Exciting access and policy-relevant news flash around the globe from the (digital) diagnostics perspective.
Does it pay off to invest in diagnostics in the LMICs?
What are the key diagnostics access & policy developments from 2021?
3 interesting reimbursement, policy learnings in oncology diagnostics (EDL, liquid biopsy, breast cancer recurrence risk scores)
What’s new in the WHO Essential Diagnostics List 3.0?
Matching Essential Diagnostics to Treatment for Global Oncology
Cost cutting in the Swiss Healthcare System (diagnostics perspective)
Swiss healthcare minister Alain Berset has announced intentions to save 1 billion CHF for the healthcare system, whilst improving care efficiency. To achieve this goal, 9 initiatives were proposed on the 19th of August, which are now undergoing public consultation.
The following is Centivis’ current understanding based on publicly available documents. However, we acknowledge that the situation may change depending on the results of the public consultation.
U.S. Lab Test Reimbursement Rates: What’s New(s)? (updated January, 2020)
U.S. Lab Test Reimbursement Rates: What’s New(s)?
WHO’s Essential Diagnostics List - Version 2; What’s new?
(VIDEO) 3+1 Policy Initiatives That Will Influence Diagnostics (IVD) Access
3+1 Policy Initiatives That Will Influence Diagnostics (IVD) Access
The diagnostics industry is facing increasing policy attention. Policymakers push for broader access, better affordability and safer than ever solutions. Institutions, like the European Union (EU) and World Health Organization (WHO), are involved in introducing new regulations.
Find out what are the latest policy initiatives and how will they impact access for IVD solutions.
India drafts its own Essential Diagnostics List following WHO's
WHO's Essential Diagnostics List in a 2-minute video
If a picture is worth a thousand Words, what is a video worth?
We took a complex topic, WHO's Essential Diagnostics List and condensed it in a 2-minute video...What do you think about the format and content?
Please comment.
Thanks Norbert
WHO Essential Diagnostics List (EDL) – 3 likely impacts to the diagnostics industry
WHO Essential Diagnostics List (EDL) – 3 likely impacts to the diagnostics industry
The diagnostics industry is facing increasing policy attention. The In Vitro Diagnostic Device Regulation (IVDR) will newly regulate the European approval system, the new EU Health Technology Assessment (HTA) proposal is already on the table and World Health Organization (WHO) has just released the first Essential Diagnostics List (EDL).
Similar concept, Essential Medicines List (EML) has been around for 40 years. Looking at the history of EML what can the diagnostics industry expect?